Samfara Acquires Chr. Olesen Synthesis Expanding Controlled-Substance APIs Market Presence
News related to:Chr. Olesen Synthesis · 1 min read
LONDON, Oct. 2, 2026 /CourierPR/ -- Samfara, a European life sciences investment firm based in London, has completed its first major acquisition by purchasing Chr. Olesen Synthesis, a Danish manufacturer of controlled-substance active pharmaceutical ingredients (APIs). The deal, backed by a syndicate of European and North American institutional investors and family offices, marks a significant move for Samfara in expanding its portfolio.
Chr. Olesen Synthesis, based near Copenhagen, has been in commercial production since 2015. The company specializes in developing and manufacturing APIs and advanced intermediates, with a particular focus on controlled substances, including those used to treat opioid use disorder and ADHD. Its cGMP-certified plant supplies pharmaceutical companies across Europe, North America, and the Middle East, offering contract development and manufacturing services for new APIs.
The acquisition is seen as a strategic move for Samfara, which aims to support the growth and development of Chr. Olesen Synthesis. Jean-François Hilaire, a former CEO of Unither and former EVP at Recipharm, will join the board of Chr. Olesen Synthesis as Chair, bringing valuable industry experience to the company.
Thomas Moestrup, Chief Executive of Chr.
Mads C. Olesen, Chief Executive and owner of Chr.
Chr. Olesen Synthesis, a Danish developer and manufacturer of APIs and advanced intermediates, has been in commercial production since 2015. Chr. Olesen, founded in 1885, is a family-owned global distribution company specializing in nutraceutical ingredients for the feed, food, pharma, and technical industries. Signet Healthcare Partners, a healthcare growth equity firm, has invested in more than 60 companies, supporting entrepreneurs with capital, strategic guidance, and deep industry networks.
Samfara's backing will enable Chr. Olesen Synthesis to continue its growth and expand its market presence. The company will leverage its existing customer relationships and product offerings to explore new opportunities, both organically and through acquisitions. With the support of Samfara and the expertise of its new board members, Chr. Olesen Synthesis is poised for continued success in the complex and demanding pharmaceutical market.